Clinical Trial Update: Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating eculizumab for dense deposit disease and C3 nephropathy has completed, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Nephropathy
• Dense Deposit Disease
• Membranoproliferative Glomerulonephritis

Drugs mentioned

• SOLIRIS (eculizumab)

Snippet

Sponsor: Columbia University | Conditions: Dense Deposit Disease, Membranoproliferative Glomerulonephritis | Phase 1 | Status: COMPLETED | Results posted: 2019-02-19